Actos 30 Mg 30 Tablets

Actos 30 Mg 30 Tablets

Description:

Actos 30 mg 30 tablets is a prescription oral antidiabetic medicine used to help control blood glucose levels in adults with type 2 diabetes mellitus. Each film‑coated tablet contains 30 mg of pioglitazone (as pioglitazone hydrochloride), a thiazolidinedione that improves the body’s sensitivity to insulin. By enhancing insulin action in muscle, fat, and liver cells, Actos helps reduce insulin resistance, lower fasting and post‑meal blood sugar, and improve overall glycemic control. It is typically used as an adjunct to a calorie‑controlled diet, weight management, and regular physical activity, either alone or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. Actos is intended for long‑term management of type 2 diabetes under medical supervision to help reduce the risk of diabetes‑related complications.

Indications:

• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• Monotherapy in patients with type 2 diabetes who are inadequately controlled with lifestyle measures alone.
• Combination therapy with metformin, sulfonylureas, or insulin when these agents alone do not provide adequate blood glucose control.
• Helps reduce elevated fasting blood glucose and postprandial (after‑meal) blood glucose levels.
• Indicated for adults aged 18 years and older with type 2 diabetes; not indicated for type 1 diabetes or diabetic ketoacidosis.

Active Ingredients / Key Components:

• Pioglitazone (as pioglitazone hydrochloride) – 30 mg per tablet.
• Other tablet excipients (such as fillers, binders, coating agents, and colorants) are present but specific inactive ingredients and their concentrations , please check the product leaflet or the manufacturer’s official website.

Dosage & Administration / How to Use:

• Usual adult dose: 30 mg orally once daily, taken at approximately the same time each day, as prescribed by your doctor.
• May be taken with or without food; swallow the tablet whole with a glass of water. Do not crush, chew, or break the tablet.
• Your doctor may adjust the dose based on blood glucose response, tolerability, and concomitant antidiabetic medications. Do not change your dose without medical advice.
• Use Actos as part of a comprehensive diabetes management plan including a balanced diet, regular exercise, and weight control.
• If you miss a dose, take it as soon as you remember unless it is almost time for your next dose. In that case, skip the missed dose and resume your regular schedule. Do not double the dose.
• Regularly monitor blood glucose (and HbA1c as advised) to assess treatment effectiveness. Your doctor may also request periodic liver function tests and assessments for fluid retention or heart failure.
• Continue taking Actos even if you feel well, unless your doctor instructs you to stop. Stopping suddenly may worsen blood sugar control.
• Use with caution and under close supervision when combined with insulin or insulin secretagogues (such as sulfonylureas), as the risk of hypoglycemia may increase; dose adjustments of the other agents may be required.

Clinical Benefits:

• Improves insulin sensitivity in peripheral tissues, helping the body use its own insulin more effectively.
• Helps lower fasting and post‑meal blood glucose levels and improves overall glycemic control (HbA1c) in adults with type 2 diabetes.
• Can be used as monotherapy or in combination with other oral antidiabetic drugs or insulin for flexible, individualized treatment regimens.
• Supports long‑term management of type 2 diabetes, helping to reduce the risk of microvascular and macrovascular complications when used as part of a comprehensive care plan.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to pioglitazone or any component of the formulation.
• Contraindicated in patients with current or a history of heart failure (especially New York Heart Association Class III or IV) due to risk of fluid retention and worsening heart failure.
• Not recommended in patients with active bladder cancer or a history of bladder cancer, or in patients with unexplained macroscopic hematuria that has not been investigated.
• Use with caution in patients with edema, cardiovascular disease, or risk factors for heart failure. Monitor for rapid weight gain, shortness of breath, or swelling of the legs or ankles.
• Use with caution in patients with liver disease; baseline and periodic liver function tests are recommended. Discontinue if jaundice or significant liver enzyme elevation occurs.
• May increase the risk of bone fractures, particularly in women; consider fracture risk in long‑term therapy.
• Not indicated for type 1 diabetes or for the treatment of diabetic ketoacidosis.
• Use during pregnancy or breastfeeding is not recommended unless clearly needed and prescribed by a specialist; discuss potential risks and benefits with your doctor.
• May cause or worsen macular edema; report any visual changes promptly.
• Consult your doctor before use if you are pregnant, planning pregnancy, breastfeeding, have heart disease, liver disease, bladder problems, eye disease, or are taking other medications that affect blood sugar.
• Keep out of reach of children.

Side Effects:

• Common side effects: weight gain, edema (swelling of ankles, feet, or hands), headache, muscle pain, upper respiratory tract infections, and sinusitis.
• Metabolic effects: hypoglycemia (low blood sugar) may occur, especially when used with insulin or sulfonylureas; symptoms include sweating, tremor, hunger, dizziness, or palpitations.
• Cardiovascular effects: fluid retention and heart failure or worsening of pre‑existing heart failure; seek urgent medical attention if you experience shortness of breath, rapid weight gain, or swelling.
• Ocular effects: macular edema (swelling at the back of the eye) may cause blurred or decreased vision; report any visual changes immediately.
• Hepatic effects: rare cases of liver dysfunction; symptoms may include nausea, vomiting, abdominal pain, fatigue, dark urine, or yellowing of the skin or eyes.
• Other serious but less common effects: increased risk of bladder cancer with long‑term use, especially in high cumulative doses; report blood in urine, painful urination, or urinary urgency.
• Allergic reactions: rash, itching, swelling of the face, lips, tongue, or throat, severe dizziness, or difficulty breathing require immediate medical attention.

Storage Instructions:

Store in a cool, dry place away from direct sunlight and moisture. Keep the blister pack or container tightly closed. Do not store above the temperature specified on the package (exact temperature not available in the provided information). Keep out of reach of children. Do not use after the expiry date printed on the pack, and do not use tablets that are damaged or show signs of deterioration.

Specifications:

• Product type: oral antidiabetic medicine (pioglitazone).
• Strength: 30 mg pioglitazone per tablet.
• Form: film‑coated tablet for oral use.
• Pack size: 30 tablets per pack.
• Intended user group: adults with type 2 diabetes mellitus, as prescribed by a healthcare professional.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.